PHAP Head Calls for Prioritizing Essential Medicines Amid Global Market Uncertainty | News and Views
Why It Matters
Ensuring a reliable, affordable supply of essential medicines shields Filipino patients from price volatility and positions the country to reduce dependence on volatile import routes.
Key Takeaways
- •Philippine medicine supply remains stable with 2‑3 month buffer.
- •Middle East crisis raises shipping costs, risking future price spikes.
- •PHP urges 6‑month buffer and 2026 supply security for essential drugs.
- •Prioritize life‑saving imports like insulin, vaccines, biologics for local production.
- •Government procurement pooling can lock volume, stabilize prices, reduce costs.
Summary
The Philippine Pharmaceutical and Health Association (PHAP) head warned that, despite a currently stable drug supply, the ongoing Middle‑East geopolitical crisis and rising jet‑fuel costs could soon destabilize the market for essential medicines in the Philippines.
PHAP members report a two‑to‑three‑month buffer of inventory, but shipping expenses have jumped about 30 % and logistics delays are already being absorbed by manufacturers. The association stresses that this cushion is unsustainable and that a six‑month buffer—ideally extending through 2026—is needed to guard against further disruptions.
Key recommendations focus on identifying life‑saving imports such as insulin, vaccines and oncology biologics, which cannot yet be produced locally and may require 12‑24 months to manufacture. PHAP also proposes leveraging pooled government procurement and multi‑year contracts with regional partners like Vietnam, Thailand and Singapore to secure volume and price stability.
If policymakers adopt these measures—providing fiscal incentives for local manufacturing and expanding strategic stockpiles—the Philippines can protect patients from price hikes and supply shortages, while strengthening its pharmaceutical self‑reliance.
Comments
Want to join the conversation?
Loading comments...